GET DAILY SIGNALSNeurAxis (NRXS) Price Target of $11 Suggests +49% Upside Potential
Key Takeaways
- The central stock price target of $11 is the arithmetic mean of two verified analyst price targets, which span roughly $9 to $13.
- At a recent price near $7.36, reaching $11 would require a gain of about 49%, a substantial but not unprecedented move for this small-cap name.
- Supporting factors include rapid revenue growth, expanding insurance coverage, a new billing code, and a Strong Buy analyst consensus.
- The biggest risks are continued net losses, heavy reliance on payer adoption, a small float, and a stock that has already re-rated sharply over the past year.
- You can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots to see how AI-driven strategies are monitoring stocks like this one.
Analyst Price Targets and Consensus View
NeurAxis, Inc. (NRXS) is a growth-stage medical technology company, not an ETF, that develops neuromodulation therapies for gastrointestinal conditions in children and adults. Its lead product is IB-Stim, a non-surgical electrical nerve stimulation device cleared for functional abdominal pain associated with irritable bowel syndrome.
Coverage of this micro-cap is thin. Aggregators such as StockAnalysis and Investing.com, drawing on S&P Global data, report two covering analysts with a 12-month price forecast ranging from about $9 on the low end to $13 on the high end. The arithmetic mean of those two targets is $11, which rounds cleanly to the $11 central target used here. The most recently verifiable individual target is a $13 Buy from Craig-Hallum analyst Chase Knickerbocker, raised from $8 in March 2026. A separate, lower target sits near $9. Because only two analysts cover the stock, the "average analyst price target" should be read as a narrow sample rather than a broad analyst consensus, and the $9-to-$13 range reflects genuine uncertainty about how quickly adoption scales. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The shares closed near $7.36 in late October 2026, within a 52-week range of roughly $2.21 to $9.33. Reaching $11 from that level implies upside of close to 49%, a substantial move for a company whose market capitalization is still under $100 million. NeurAxis grew 2025 revenue about 33% to $3.57 million, then accelerated sharply: first-quarter 2026 revenue rose about 80% year over year and second-quarter revenue roughly 116%, with gross margins above 85%. The company remains unprofitable, reporting net losses that widened modestly in 2025. The path toward a higher valuation therefore rests less on current earnings, which are negative, and more on sustained revenue acceleration, rising insurance-covered lives, and progress toward eventual profitability.
What Could Support a Move Toward the Target
- Payer coverage expansion. The company has announced a growing national coverage footprint, now exceeding roughly 147 million covered lives, including a medical-necessity designation from CVS Health's Aetna for IB-Stim.
- Reimbursement catalyst. A new Category 1 CPT code supports more standardized billing and could smooth adoption.
- Expanding addressable market. A multi-site adult clinical trial launched in late 2026, potentially broadening use beyond the pediatric focus.
- Operating leverage. Gross margins above 85% and declining cash burn give the business a credible path toward profitability if revenue keeps compounding.
- Index inclusion. The stock was added to Russell microcap indexes, which can modestly increase institutional visibility.
What Could Prevent the Target From Being Reached
- Persistent losses. The company still burns cash and has periodically raised capital, which can dilute existing shareholders.
- Payer concentration. Growth depends heavily on winning and maintaining insurance coverage decisions that are outside the company's control.
- Small float and volatility. With a limited share count and a beta above 1.3, the stock can swing sharply on modest news in either direction.
- Valuation re-rating risk. After a large percentage gain over the past year, independent fair-value models have at times suggested the market price already reflects much of the near-term opportunity.
Technical Levels and Market Structure
NeurAxis set an all-time high near $9.33 in May 2026, and that level now acts as the clearest resistance level on the way to $11; a decisive break above it would remove a key prior ceiling. To the downside, the $9 and then lower-$7 zones are areas where buyers have previously stepped in, providing potential support level references. A move to $11 would also cross the psychologically significant $10 threshold, which can act as a magnet or a hurdle depending on broader sentiment. The long-term trend remains upward, but the stock's history of rapid rallies and sharp pullbacks warrants caution around round numbers.
Time Horizon and What Investors Should Monitor
Analyst targets for this stock are typically framed on a roughly 12-month research horizon, though the two covering firms have not published identical timelines. Investors should watch the upcoming quarterly results and business update, scheduled for November 9, 2026, for revenue trajectory and cash-burn commentary; any new or expanded payer policy decisions; progress on the adult clinical trial; and any analyst target or rating revisions given how few cover the name. Changes in small-cap and healthcare-sector risk appetite also matter for a high-beta stock of this size. From what I see, the next earnings release will be particularly telling.
Using AI Daily Buy/Sell Signals for Ongoing Monitoring
For traders who want a continuous, systematic read on names like NeurAxis, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The system uses artificial intelligence to monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. By surfacing shifts in momentum and trend more efficiently than manual screening, it can help traders discover new opportunities, monitor existing positions, and spot changing patterns before they become obvious. I’m watching this closely as part of my routine process.
Final Assessment
Can NRXS reach $11? The question hinges on whether the company can convert accelerating revenue and expanding insurance coverage into a durable, re-rated growth story. The $11 central target, drawn from a two-analyst mean within a $9-to-$13 range, implies roughly 49% upside from the recent price near $7.36. The bull case rests on strong top-line momentum, exceptional gross margins, and broadening payer access; the bear case points to ongoing losses, financing needs, and the risk that much of the optimism is already priced in after a large run. With such thin coverage and high volatility, the stock can move quickly in either direction, and the next earnings report plus any new coverage decisions are the clearest near-term signposts.
Exploring Tickeron AI Tools for Deeper Analysis
In my own research workflow, I often turn to Tickeron’s suite of AI tools to cross-check ideas and surface patterns across a wide universe of names. The AI Daily Buy/Sell Signals platform stands out for its ability to deliver real-time, systematic signals that complement traditional analysis. It helps flag momentum shifts and trend changes that might otherwise go unnoticed, giving a clearer picture of how a stock like NRXS is behaving relative to its peers. I find it especially useful when coverage is thin and quick adjustments matter.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NRXS turns positive, indicating new upward trend
NRXS saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 67 similar instances where the indicator turned positive. In 62 of the 67 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
NRXS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NRXS crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +19.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 122 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for NRXS moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 32 cases where NRXS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 29 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.731) is normal, around the industry mean (2.974). P/E Ratio (-9.684) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement